Likely only safety as the first steps of any dose escalation study are usually below the therapeutically effective dose. The answer also depends on what dose level ethics lets us start at.
I would also add that RC220 going into humans via a peripheral vein with no problems would be a major piece of valuable clinical data.
- Forums
- ASX - By Stock
- RAC
- Ann: December 2023 Preclinical & Clinical Program Update
Ann: December 2023 Preclinical & Clinical Program Update, page-45
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.61 |
Change
-0.045(2.73%) |
Mkt cap ! $273.5M |
Open | High | Low | Value | Volume |
$1.66 | $1.66 | $1.61 | $159.4K | 98.03K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 5684 | $1.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.62 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 5684 | 1.605 |
2 | 1134 | 1.600 |
4 | 5932 | 1.580 |
1 | 6000 | 1.560 |
5 | 6622 | 1.550 |
Price($) | Vol. | No. |
---|---|---|
1.620 | 2000 | 1 |
1.650 | 7731 | 1 |
1.685 | 5000 | 1 |
1.690 | 3316 | 2 |
1.700 | 6580 | 1 |
Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |